Surveillance AFter Extremity Tumor surgerY (NCT03944798)
Surveillance AFter Extremity Tumor surgerY (SAFETY) International Randomized Controlled Trial
🩺 Plain-English Summary (8th-Grade Level)
Following treatment for a primary extremity sarcoma, patients remain at risk for the development of local and systemic disease recurrence. Metastasis (distant recurrence) to the lung is the most frequent single location of disease recurrence in sarcoma patients, occurring in almost half of all patients. Therefore, careful post-operative surveillance is an integral element of patient care. However, the detection of metastases does not necessarily affect long-term survival and may negatively impact quality of life. Surveillance strategies have not been well researched and have been identified as the top research priority in the extremity sarcoma field. Using a 2X2 factorial design to maximize efficiency and reduce overall trial costs, the SAFETY trial randomized 310 extremity soft-tissue sarcoma (STS) patients to determine the effect of surveillance strategy on overall patient survival after surgery for a STS of the extremity by comparing the effectiveness of both surveillance frequency (every 3 vs. every 6 months) and imaging modality (CT scans vs. chest radiographs).
Who can join: Review the eligibility criteria below.
Location: University of California Davis Medical Center — Sacramento, California
Age range: 18 Years
🧪 Interventions in This Study
- Frequency: Every 3 Months (OTHER)
- Frequency: Every 6 Months (OTHER)
- Imaging Modality: Chest Radiograph (CXR) (OTHER)
- Imaging Modality: Chest CT (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (35 Sites)
Showing the first 25 of 35 sites.
- University of California Davis Medical Center — Sacramento, California
- Hartford HealthCare — Hartford, Connecticut
- University of Florida Health Shands Hospital — Gainesville, Florida
- UChicago Medicine — Chicago, Illinois
- Parkview Cancer Institute — Fort Wayne, Indiana
- Holden Comprehensive Cancer Center — Iowa City, Iowa
- Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire
- Albany Medical Center — Albany, New York
- NYU Langone Orthopaedic Hospital/Perlmutter Cancer Center — New York, New York
- Montefiore Medical Center — The Bronx, New York
- Cleveland Clinic — Cleveland, Ohio
- Oregon Health and Science University Hospital — Portland, Oregon
- Allegheny Health Network Research Institute — Monroeville, Pennsylvania
- Texas Tech Health Sciences Center — El Paso, Texas
- Huntsman Cancer Institute — Salt Lake City, Utah
- Fred Hutchinson Cancer Center — Seattle, Washington
- Hospital Universitario Austral — Buenos Aires,
- St. Vincent's Hospital Melbourne — Fitzroy, Melbourne
- LKH - Universitätsklinikum Graz — Graz,
- Cliniques Universitaires Saint-Luc — Brussels,
- Hospital de Clínicas de Porto Alegre — Porto Alegre,
- Nova Scotia Health — Halifax, Nova Scotia
- Juravinski Hospital and Cancer Centre — Hamilton, Ontario
- The Ottawa Hospital — Ottawa, Ontario
- Mount Sinai Hospital — Toronto, Ontario
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Soft Tissue Sarcoma
- Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma — St Louis, Missouri
- Dose Reduction of Postoperative Radiation for Soft Tissue Sarcoma of the Arms and Legs — Basking Ridge, New Jersey
- Hypofractionated Radiotherapy for Soft Tissue Sarcomas — Madison, Wisconsin
- TVEC and Preop Radiation for Sarcoma (8 ml Dose) — Iowa City, Iowa
- Study to Assess TOPO2A as a Biomarker for Sensitivity to Doxorubicin/Doxil in Soft Tissue Sarcoma — Philadelphia, Pennsylvania
- A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma — Houston, Texas
Explore by condition: All Soft Tissue Sarcoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.